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Abstract 
BACKGROUND: Anetodermas are rare disorders of connective tissue with a focal loss of elastic fibres in the 
upper and mid dermis. Two types are separated, inflammatory and non-inflammatory. 
CASE REPORTS: We report two cases of acquired anetoderma Schweniger-Buzzi type. This non-inflammatory 
subtype is characterised by skin-coloured or whitish atrophic sac-like protrusions of trunk skin in adult males. 
Chronic infections and autoimmune disorders have been excluded. The diagnosis had been confirmed by 
characteristic histopathology. 
CONCLUSIONS: Anetodermas are symptomless disorders. They can be easily overlooked. The knowledge of 
such conditions is of importance to identify patients with a risk of thromboembolic events and underlying infections 
or autoimmune connective tissue diseases. 
 
 
 
 
 
 
 
Introduction 
 
Cutaneous elastic tissue anomalies are 
classified as those with increased or abnormal elastic 
tissue and those with a loss of elastic tissue. To the 
first group belong disorders such as nevus elasticus, 
pseudoxanthoma elasticum, or elastosis perforans 
serpinginosa. Papular elastorrhexis, mid dermal 
elastolysis and anetoderma fall under the second 
group [1].  
The loss of elastic tissue can be by decreased 
production of elastic fibers, increased activity of 
elastase and matrix metalloproteinases, activation of 
phagocytosis of elastic fibres by macrophages or a 
combination of these [2]. Here we report two cases of 
the rare anetoderma Schweninger-Buzzi type in two 
adult males.  
 
Case Reports 
 
Case 1: A 48-year old male was referred from 
the rheumatologist to exclude scleroderma. The 
patient reported the development of asymptomatic 
skin lesions on his trunk. He was otherwise healthy 
and had no medical drug therapy.  
On examination, we observed more than 100 
skin-coloured herniated sac-like lesions on the trunk 
arranged in Langer’s lines. The maximum diameter 
was about 1 cm. There was no erythema, no scaling, 
no pruritus (Figure 1). 
Laboratory findings, including antinuclear 
antibodies (ANA), anti-cardiolipin antibodies, and 
Borrelia serology, were normal or negative. 
A skin biopsy was obtained for histology. 
Narrowed collagen fibres were noted in the whole 
Global Dermatology 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2                                                                                                                                                                                                   https://www.id-press.eu/mjms/index 
 
dermis. In the upper dermis, there was a focal loss of 
elastic fibres. The skin appendages were preserved. 
An inflammatory infiltrate completely missing. 
 
Figure 1: Anetoderma (case #1) 
 
Case 2: A 33-year-old male presented with 
multiple asymptomatic lesions on the back. His 
medical history was unremarkable. He did not use any 
medical drugs. 
On examination, we observed skin-coloured 
sac-like herniated lesions with a size of up to 7 mm 
arranged along Langer’s lines (Figure 2).  
 
Figure 2: Anetoderma (case #2) 
 
Laboratory investigations demonstrated 
antimitochondrial antibodies 1:320, mild eosinophilia 
of 9.6%. Borrelia serology and ANA screening 
remained negative. 
 
Figure 3: Histopathology of anetoderma Schweninger-Buzzi, case 
#2; A) Hematoxylin-eosin; B) elastica stain (x 4) 
 
A skin biopsy revealed the same pattern as in 
the first patient (Figure 3).  
In both patients, the diagnosis of anetoderma 
Schweninger-Buzzi type was confirmed by clinical 
appearance and histologic findings. 
 
 
Discussion  
 
Anetoderma is a rare disease. It belongs to 
the acquired connective tissue disorders and is 
characterised by localised skin atrophy and loss of 
elastic fibres [3]. In electron microscopy, fibre 
fragments have been described [4].  
Traditionally, anetoderma has been 
differentiated into an inflammatory subtype 
Jadassohn-Pellizari with prodromal urticaria-like 
lesions, followed by erythematous atrophic lesions [5]. 
The type Schweninger-Buzzi develops spontaneously 
without inflammation [6]. Lesions are either skin-
coloured or whitish [7]. Hereditary antoderma is 
extremely rare [8]. 
Primary anetoderma can be a precursor of 
autoimmune disorders and a marker for prothrombotic 
conditions like anti-phospholipid syndrome [7], [9], 
[10]. Secondary anetoderma has been reported after 
granuloma annulare [11], secondary syphilis [12], 
pilomatricoma [13], and bullous Sweet syndrome [14]. 
Acquired anetoderma following folliculitis is known in 
patients with Down syndrome [15].  
Infection with Borrelia afzelii has been 
considered a possible cause of secondary 
anetoderma as well [16], [17]. Since Lyme borreliosis 
is common in Southern Germany [18], it was of 
particular importance to rule out Borrelia infection in 
our cases (Table 1). 
Table 1: Anetoderma – underlying pathologies 
Type Pathologies 
Primary anetoderma  Autoimmune inflammation (connective 
tissue disorders) 
Thromboembolic events (anti-phospholipid 
syndrome, anti-thrombin III deficiency) 
Secondary anetoderma Infectious diseases (Lyme disease, syphilis, 
HIV, leprosy) 
Inflammatory disorders (granuloma 
annulare, Sweet Syndrome, Stevens-
Johnson syndrome, folliculitis) 
Drug induced (penicillamine, penicillin) 
Metabolic disorders (Wilson’s disease) 
Tumor-associated (Reed syndrome, 
pilomatricoma, 
cutaneous lymphomas, xanthogranuloma) 
 
 
Differential diagnoses include morphea, cutis 
laxa, pseudoxanthoma elasticum-like papillary 
elastolysis, lichen sclerosus et atrophicus, 
lepromatous leprosy, and chalazodermic amyloidosis 
[1], [19], [20].  
Treatment is dependent upon underlying 
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pathologies. Infectious disorders need antibiosis; 
inflammatory disorders require immune-modulating 
drugs and tumours warrant surgery, radiotherapy or 
anti-tumour drugs. Successful treatment of the 
underlying pathology may result in the prevention of 
the development of additional lesions. Once 
anetoderma has developed, there is no specific drug 
therapy for the condition available. Corticosteroids, 
dapsone, colchicine, aminocaproic acid, vitamin E, 
and niacin yielded meager improvement. Peels and 
radiofrequency devices have occasionally been 
employed [21]. Laser therapy has been used to 
improve the appearance by stimulation of the 
production of elastic fibres and a decrease in fibre 
fragmentation after combined 595 nm pulsed-dye 
laser plus 1550 nm non-ablative fractionated laser [22] 
and 10,600 nm CO2 laser [23] [24]. In analogy to 
depressed scars, dermal filler injections may have a 
lifting effect [25]. 
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